Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2019, provides an overview of the Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline landscape.

Onychomycosis is a chronic fungal infection of the nails caused by dermatophytes. Symptoms include thickened nail that is difficult to cut, brittle or ragged nail, discolored or unsightly nail and pain of the finger or toe with ordinary activities. Treatment includes antifungal medications and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Onychomycosis (Tinea Unguium) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Onychomycosis (Tinea Unguium) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 7, 2, 2, 1 and 1 respectively.

Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Onychomycosis (Tinea Unguium) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Onychomycosis (Tinea Unguium) (Infectious Disease) by companies and universities/research institutes based on information derived from
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Onychomycosis (Tinea Unguium) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Onychomycosis (Tinea Unguium) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Onychomycosis (Tinea Unguium) (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Onychomycosis (Tinea Unguium) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table Of Contents:

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Onychomycosis (Tinea Unguium) - Overview
Onychomycosis (Tinea Unguium) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Onychomycosis (Tinea Unguium) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Onychomycosis (Tinea Unguium) - Companies Involved in Therapeutics Development
Almirall SA
Blueberry Therapeutics Ltd
Hexima Ltd
Kaken Pharmaceutical Co Ltd
Meiji Seika Pharma Co Ltd
Moberg Pharma AB
NAL Pharmaceuticals Ltd
Novabiotics Ltd
Novan Inc
Viamet Pharmaceuticals Inc
Onychomycosis (Tinea Unguium) - Drug Profiles
Amphotericin B sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BB-0305 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ELS-160 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HXP-124 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KP-607 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Onychomycosis (Tinea Unguium) - Dormant Projects
Onychomycosis (Tinea Unguium) - Discontinued Products
Onychomycosis (Tinea Unguium) - Product Development Milestones

Featured News & Press Releases

Nov 23, 2018: Moberg Pharma: Patent granted for MOB-015 in China
Sep 11, 2018: Moberg Pharma has completed enrollment to Phase 3 study for MOB-015 in North America
May 17, 2018: SB208 Increases Daily Nail Growth Rate over Four Weeks of Treatment
Jan 11, 2018: Novan to Present Positive Phase 2 Results for SB208 Antifungal Program at Winter Clinical Dermatology Conference
Nov 20, 2017: Moberg Pharma replaces CRO in Phase 3 studies for MOB-015
Nov 08, 2017: Moberg Pharma provides update on timeline for MOB-015
Jul 27, 2017: Viamet to Present Data on VT-1161 for the Treatment of Onychomycosis at the American Podiatric Medical Association Annual Meeting
Jun 21, 2017: Viamet to Present Data on VT-1161 for the Treatment of Onychomycosis at the 4th International Summit on Nail Diseases
Apr 12, 2017: Novan Reports Positive Topline Results with SB208 in Phase 2 Trial
Mar 06, 2017: Viamet Presents Positive Results from Phase 2b Trial of VT-1161 in Onychomycosis at the American Academy of Dermatology Annual Meeting
Mar 01, 2017: Viamet Announces RENOVATE Phase 2b Onychomycosis Results to be Presented at the American Academy of Dermatology 2017 Annual Meeting
Nov 08, 2016: Hallux Announces Start of Phase 2 Clinical Trial
Sep 28, 2016: Moberg Pharma Begins Patient Enrollment in North America and Europe in Two Phase 3 Studies of MOB-015 in Onychomycosis
Aug 10, 2016: Moberg Pharma Announces Approvals to Start Phase 3 Study For MOB-015 In U.S. And Canada
Jul 21, 2016: Novan Announces First Patient Dosed in Phase 2 Anti-Fungal Program

Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
List of Tables
Number of Products under Development for Onychomycosis (Tinea Unguium), H1 2019
Number of Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019
Number of Products by Stage and Target, H1 2019
Number of Products by Stage and Mechanism of Action, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Onychomycosis (Tinea Unguium) - Pipeline by Almirall SA, H1 2019
Onychomycosis (Tinea Unguium) - Pipeline by Blueberry Therapeutics Ltd, H1 2019
Onychomycosis (Tinea Unguium) - Pipeline by Hexima Ltd, H1 2019
Onychomycosis (Tinea Unguium) - Pipeline by Kaken Pharmaceutical Co Ltd, H1 2019
Onychomycosis (Tinea Unguium) - Pipeline by Meiji Seika Pharma Co Ltd, H1 2019
Onychomycosis (Tinea Unguium) - Pipeline by Moberg Pharma AB, H1 2019
Onychomycosis (Tinea Unguium) - Pipeline by NAL Pharmaceuticals Ltd, H1 2019
Onychomycosis (Tinea Unguium) - Pipeline by Novabiotics Ltd, H1 2019
Onychomycosis (Tinea Unguium) - Pipeline by Novan Inc, H1 2019
Onychomycosis (Tinea Unguium) - Pipeline by Viamet Pharmaceuticals Inc, H1 2019
Onychomycosis (Tinea Unguium) - Dormant Projects, H1 2019
Onychomycosis (Tinea Unguium) - Dormant Projects, H1 2019 (Contd..1), H1 2019
Onychomycosis (Tinea Unguium) - Discontinued Products, H1 2019

List of Figures
Number of Products under Development for Onychomycosis (Tinea Unguium), H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products by Targets, H1 2019
Number of Products by Stage and Targets, H1 2019
Number of Products by Mechanism of Actions, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019

Companies Mentioned:
Almirall SA
Blueberry Therapeutics Ltd
Hexima Ltd
Kaken Pharmaceutical Co Ltd
Meiji Seika Pharma Co Ltd
Moberg Pharma AB
NAL Pharmaceuticals Ltd
Novabiotics Ltd
License Types:

Single User License (PDF)

- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other person or persons.
- Unless an Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

- This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
- Unless an Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

- This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
- Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
- These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.